SymBio Pharmaceuticals

TYO: 4582

JPY17139m market cap

JPY208 last close

SymBio is a Japanese specialty pharma company with a focus on oncology and haematology. Treakisym is SymBio’s branded formulation of bendamustine HCl. Rigosertib was in-licensed from Onconova.

Investment summary

SymBio is a speciality pharma focused on Asia-Pacific markets, and has in-licensed two orphan blood cancer products. Treakisym i.v. was approved for r/r low grade NHL/MCL in 2010 and in 2016 received approvals in CLL and first-line low grade NHL/MCL; these new approvals saw in-market Treakisym sales increase by 12% in 2018, following 61% growth in 2017 (NHI price basis). SymBio has in-licensed liquid formulations for injection that will provide Treakisym with patent protection to 2031; a clinical trial is underway of the rapid-infusion liquid formulation which would reduce Treakisym infusion time from 60 minutes to 10 minutes. A Phase III trial of Treakisym in r/r diffuse large B-cell lymphoma is underway. Rigosertib i.v. is in development for r/r higher-risk myelodysplastic syndromes (HR-MDS) and is in a pivotal Phase III global study in 360 patients; SymBio is enrolling patients in Japan and is aiming for potential filing in 2021. SymBio intends to participate in a planned global trial of high-dose oral rigosertib in untreated HR-MDS.

Y/E Dec
Revenue (¥m)
EBITDA (¥m)
PBT (¥m)
EPS (¥)
P/E (x)
P/CF (x)
2016A 2368.0 (2101.0) (2317.0) (59.0) N/A N/A
2017A 3444.0 (3917.0) (3977.0) (79.8) N/A N/A
2018E 4203.0 (3004.0) (3030.0) (46.0) N/A N/A
2019E 4325.0 (3591.0) (3617.0) (46.5) N/A N/A
Last updated on 19/03/2019
Industry outlook

SymBio is focused on in-licensing niche opportunities in hard-to-treat indications often overlooked by big pharma. An in-house screening process to select additional pipeline candidates for development and commercialisation will be key to driving operating leverage.

Last updated on 19/03/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (¥m) 2947
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 0.5 2.0 (5.0)
Relative* 0.3 (1.5) 1.5
52-week high/low ¥272.0/¥116.0
*% relative to local index
Key management
Fuminori Yoshida Representative Director, President & CEO
Kazuo Asakawa Corporate Officer
Kenji Murata Corporate Officer

Content on SymBio Pharmaceuticals